Monitoring Report: Respiratory Viruses - September 2025 Data

Samuel Gratzl*, PhD

Karen Gilbert Farrar*, PhD

Duy Do, PhD

Nina Masters, MPH, PhD

Brianna M Goodwin Cartwright, MS

* Denotes co-first author
Affiliations: All authors are affiliated with Truveta, Inc.

Corresponding author:
Brianna M Goodwin Cartwright
Truveta, Inc
1745 114th Ave SE, Bellevue, WA 98004
Email: briannac@truveta.com

Abstract

Background: Few sources regularly monitor hospitalizations associated with respiratory viruses. This study provides current hospitalization trends associated with six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus.

Objective: This study aims to supplement the surveillance data provided by the CDC by describing latest trends (through October 05, 2025) overall and for each respiratory virus. This study also provides valuable insight into two at-risk populations: infants and children (age 0-4) and older adults (age 65 and over).

Methods: Using a subset of real-world electronic health record (EHR) data from Truveta, a growing collective of health systems that provides more than 18% of all daily clinical care in the US, we identified people who were hospitalized between October 01, 2020 and October 05, 2025. We identified people who tested positive for any of the six respiratory viruses within 14 days of the hospitalization. We report weekly trends in the rate of hospitalizations associated with each virus per all hospitalizations for the overall population and the two high-risk sub populations: infants and children and older adults.

Results: We included 767,906 hospitalizations of 697,482 unique patients who tested positive for a respiratory virus between October 01, 2020 and October 05, 2025.

Overall, respiratory virus-associated hospitalizations declined throughout September 2025. By the last week of the month, respiratory virus-associated hospitalizations accounted for 1.9% of all hospitalizations, down from 2.6% in early September (-27.1%). Rhinovirus was the leading cause of virus-associated hospitalizations (1.0%) and remained stable across the month of September. COVID-associated hospitalizations decreased across the month (-45.1%), while influenza-, HMPV-, parainfluenza- and RSV-associated hospitalizations remained stable across the month. In children aged 0-4 years, respiratory virus-associated hospitalizations were largely stable over the month at 2.3%. Rhinovirus was the leading cause of virus-associated hospitalizations for this age group (1.7%). Test positivity for COVID declined substantially (-60.0%) in this age group, while test positivity for RSV and parainfluenza increased (+114.9% and +51.4% respectively), though RSV- and parainfluenza-related hospitalizations remained low. Among older adults (65+), hospitalizations associated with respiratory viruses declined to 2.0% (-35.9%). COVID-associated hospitalizations declined to 1.1% and test positivity also dropped; COVID remains the leading cause of virus-associated hospitalizations in the older adult age group.

Discussion: These data highlight overall declines in respiratory virus-associated hospitalizations across age groups during September 2025. In the pediatric population, hospitalization rates remained stable, with modest increases in test positivity for RSV but continued low hospitalization rates. Among older adults, both overall and COVID-associated hospitalizations declined. These trends emphasize the importance of ongoing surveillance to monitor shifting viral patterns and to guide prevention efforts, particularly for vulnerable populations such as young children and older adults.

Trends in surveillance

Overall population



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 01, 2025	2.6%	1.5%	0.1%	0.0%	0.1%	0.0%	1.0%
September 29, 2025	1.9%	0.8%	0.1%	0.0%	0.1%	0.0%	1.0%
Change (percentage)	-27.1%	-45.1%	-20.8%	-28.9%	+41.1%	+41.3%	+1.8%
Difference (percentage points)	-0.7%	-0.7%	-0.0%	-0.0%	+0.0%	+0.0%	+0.0%



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus

September 01, 2025	7.4%	15.9%	1.6%	0.7%	2.2%	0.5%	21.7%
September 29, 2025	4.5%	6.7%	1.9%	0.7%	3.6%	1.1%	20.9%
Change (percentage)	-39.6%	-57.7%	+17.8%	-3.2%	+64.7%	+95.1%	-3.8%
Difference (percentage points)	-2.9%	-9.2%	+0.3%	-0.0%	+1.4%	+0.5%	-0.8%

In the last week of September 2025, respiratory virus-associated hospitalizations accounted for 1.9% of all hospitalizations, a decrease from 2.6% at the beginning of the month (-27.1%). COVID-associated hospitalizations saw the largest decrease (-45.1%). Influenza-, HMPV-, parainfluenza-, RSV-, and rhinovirus-associated hospitalizations all remained stable across the month.

RSV and parainfluenza test positivity increased notably (+95.1% and +64.7%, respectively), while COVID test positivity fell sharply (–57.7%). Influenza test positivity increased slightly (+17.8%), HMPV remained steady, and rhinovirus continued to show the highest positivity levels (20.9%). These data suggest that respiratory virus–associated hospitalizations remained low overall; at the end of September rhinovirus accounted for the largest proportion of virus-associated hospitalizations and had the highest rate of test positivity.

Infants and children (age 0-4)



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 01, 2025	2.1%	0.7%	n/a	0.1%	0.2%	0.1%	1.5%
September 29, 2025	2.3%	0.6%	0.0%	0.0%	0.2%	0.3%	1.7%
Change (percentage)	+10.6%	-13.0%	n/a	-35.2%	-2.8%	+337.6%	+14.6%
Difference (percentage points)	+0.2%	-0.1%	n/a	-0.0%	-0.0%	+0.2%	+0.2%



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 01, 2025	9.6%	14.7%	1.5%	1.5%	6.9%	2.0%	52.9%
September 29, 2025	7.9%	5.9%	1.9%	1.9%	10.4%	4.2%	49.4%
Change (percentage)	-18.4%	-60.0%	+23.2%	+25.5%	+51.4%	+114.9%	-6.5%
Difference (percentage points)	-1.8%	-8.8%	+0.4%	+0.4%	+3.5%	+2.3%	-3.4%

In the population aged 0–4 years, respiratory virus–associated hospitalizations remained relatively stable throughout September 2025 and are now at a rate of 2.3% of all hospitalizations in this age group. RSV-associated hospitalizations rose but continued to represent a small proportion of all hospitalizations within this age group (0.3%). COVID-associated hospitalizations increased during the first half of the month, but declined slightly overall to 0.6% (-13.0%). Rhinovirus-associated hospitalizations rose during the first half of the month, declined in the second half, but ended the month 14.6% higher than at the start. Rhinovirus remained the most common viral cause of hospitalization (1.7%). HMPV and parainfluenza-associated hospitalizations were largely unchanged.

In this pediatric population RSV test positivity more than doubled (+114.9%), and parainfluenza increased moderately (+51.4%). COVID test positivity declined sharply (-60.0%), while influenza and HMPV rose slightly (+23.2% and +25.5%, respectively). Rhinovirus remained the virus with the highest test positivity rate (49.4%) despite a slight decrease (-6.5%). These data suggest that respiratory virus–associated hospitalizations are at moderate levels among young children, with rhinovirus accounting for the largest proportion in both hospitalizations and test positivity, and RSV and parainfluenza showing a moderate increase in test positivity late in the month.

Older adults (age 65 and over)



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 01, 2025	3.2%	2.2%	0.1%	0.1%	0.1%	0.0%	0.8%
September 29, 2025	2.0%	1.1%	0.1%	0.0%	0.1%	0.0%	0.8%
Change (percentage)	-35.9%	-49.2%	-20.6%	-35.0%	+78.7%	-80.5%	-2.1%
Difference (percentage points)	-1.1%	-1.1%	-0.0%	-0.0%	+0.0%	-0.0%	-0.0%



Date	Overall	COVID	influenza	HMPV	parainfluenza	RSV	rhinovirus
September 01, 2025	5.8%	15.6%	0.9%	0.5%	0.9%	0.2%	8.2%
September 29, 2025	3.5%	8.1%	1.0%	0.5%	1.4%	0.2%	9.3%
Change (percentage)	-38.8%	-48.2%	+10.2%	-11.0%	+54.9%	-13.2%	+13.1%
Difference (percentage points)	-2.2%	-7.5%	+0.1%	-0.1%	+0.5%	-0.0%	+1.1%

Among adults aged 65 years and older, respiratory virus–associated hospitalizations accounted for 2.0% of all hospitalizations in the last week of September 2025, a decrease from 3.2% at the beginning of the month (-35.9%). COVID-associated hospitalizations represented 1.1% of all hospitalizations in this age group and saw a

steady decline across the month, while rhinovirus-associated hospitalizations were stable and accounted for 0.8% of all hospitalizations. RSV-, HMPV-, influenza-, and parainfluenza-associated hospitalizations remained low and stable throughout the month.

COVID test positivity declined substantially (–48.2%). Influenza-, HMPV-, and RSV positivity remained stable, while rhinovirus continued to show the highest positivity levels (9.3%) with a modest increase (+13.1%). These data suggest that respiratory virus–associated hospitalizations remained low among older adults, with COVID and rhinovirus accounting for the largest proportions in both hospitalizations and test positivity.

Introduction

COVID, influenza, and RSV account for a large proportion of hospitalizations related to respiratory illnesses in the United States. To provide a more complete understanding of hospitalizations related to respiratory viruses, we have also included other viruses known to cause respiratory illness such as human metapneumovirus (HMPV), parainfluenza, and rhinovirus. Each of these viruses can lead to hospitalization and death especially in vulnerable populations, such as infants, children, and older adults (Pastula et al., 2017; Shi et al., 2017, Centers for Disease Control and Prevention 2023a, Smits et al., 2023). Representative and timely data to proactively monitor infections are scarce.

Respiratory viruses are also a major source of infection and hospitalizations in older adults (defined here as patients 65 years of age or older). Incidence has been estimated between 3-10% annually for RSV in older adults (Boyce et al., 2000) and 8-10% for influenza in adults (Tokars et al., 2018). Often, as is the case with influenza, older adults are at higher risk for hospitalization and death than other age groups (Czaja et al. 2019). There are comorbidities that are associated with increased hospitalization risk for older adults, such as congestive heart failure and chronic lung disease (Lee et al., 2013). Further, asthma, COPD, and congestive heart failure can exacerbate respiratory virus infections. Here we report counts for a selection of high-risk medical conditions such as chronic lung diseases and asthma.

Incidence rates in infants and children (defined here as individuals less than five years of age) with respiratory virus infections are higher than other age groups, except adults 65 and older (Centers for Disease Control and Prevention, 2023c; Centers for Disease Control and Prevention, 2023d). In the future, we plan to include high-risk comorbid

states, such as congenital heart disease, preterm birth, and cystic fibrosis (Committee on Infectious Diseases and Bronchiolitis Guidelines Committee et al., 2014).

It is important for public health experts and clinical providers to understand the trends in these infections to inform decisions about public health, clinical care, and public policy. Connecting population-level trends with granular clinical information available in Truveta Studio can be very useful to more deeply understand which cohorts are most impacted.

This report is intended to supplement the surveillance data provided by the CDC (Centers for Disease Control and Prevention, 2023b). This report includes additional independent data and clinical detail that is not captured in other reports.

Methods

Data

We evaluated respiratory virus-associated hospitalization trends of six common respiratory viruses: COVID-19, influenza, human metapneumovirus (HMPV), parainfluenza virus, respiratory syncytial virus (RSV), and rhinovirus between October 01, 2020 and October 05, 2025 using a subset of Truveta Data. Truveta provides access to continuously updated, linked, and de-identified electronic health record (EHR) from a collective of US health care systems that provide 18% of all daily clinical care in the US, including structured information on demographics, encounters, diagnoses, vital signs (e.g., weight, BMI, blood pressure), medication requests (prescriptions), medication administration, laboratory and diagnostic tests and results (e.g., COVID tests and values), and procedures. Updated EHR data are provided daily to Truveta by constituent health care systems. The data used in this study was provided on October 21, 2025 and included de-identified patient care data primarily located across ten states: California, Florida, Texas, New York, Virginia, Washington, Arizona, North Carolina, Maryland, and Louisiana.

Population

We identified hospitalized patients who tested positive for one of the selected respiratory viruses within 14 days before or during the hospitalization. Positive lab results were identified using LOINC codes. Every respiratory virus-associated hospitalization has been grouped such that every hospitalization within 90 days is considered to be the same infection and thus only counted once. To align with seasonality in respiratory transmission, time periods include October 1st through September 30th of the following year.

Hospitalization rate analysis

Characteristics of respiratory virus-associated hospitalized patients were summarized, including demographics and comorbidities by respiratory virus season. Characteristics are provided for the overall population, individual viruses, and two at-risk sub populations: infants and children (age 0-4) and older adults (age 65 and over).

Respiratory virus-associated hospitalizations rates were summarized over time by virus. The hospitalization rate was calculated weekly as the number of patients with a respiratory virus associated hospitalization divided by the number of patients with a hospital admission in that week. Patients were included in this calculation on the first day of their hospitalization. If their stay was greater than one day, they were not counted on subsequent dates.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Test positivity rate analysis

Lab results with known results were summarized over time by virus. The positivity rate was calculated monthly as the number of positive lab results divided by the total number of lab results with known results in that month.

Given the unadjusted nature of the data, the rates do not account for undertesting and other variability that exists across patient groups, providers, and systems. For further limitations, see the section below.

Results

Overall population

Our study population consists of 767,906 hospitalizations of 697,482 unique patients (Table 1).

Table 1: Patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	170,600 (100.00%)	173,709 (100.00%)	126,076 (100.00%)	123,009 (100.00%)	104,088 (100.00%)	697,482 (100.00%)
Age Group						
< 6 months	1,441 (0.84%)	2,408 (1.39%)	3,281 (2.60%)	2,798 (2.27%)	2,261 (2.17%)	12,189 (1.75%)
6 - <12 months	642 (0.38%)	1,159 (0.67%)	1,636 (1.30%)	1,516 (1.23%)	1,346 (1.29%)	6,299 (0.90%)

1 - <2 years	1,034 (0.61%)	1,688 (0.97%)	2,229 (1.77%)	2,061 (1.68%)	2,135 (2.05%)	9,147 (1.31%)
2 - 4 years	1,164 (0.68%)	2,514 (1.45%)	3,220 (2.55%)	2,617 (2.13%)	2,807 (2.70%)	12,322 (1.77%)
5 - 17 years	1,919 (1.12%)	3,119 (1.80%)	3,775 (2.99%)	3,728 (3.03%)	3,813 (3.66%)	16,354 (2.34%)
18 - 49 years	39,460 (23.13%)	35,706 (20.56%)	17,808 (14.12%)	16,992 (13.81%)	15,166 (14.57%)	125,132 (17.94%)
50 - 64 years	42,890 (25.14%)	35,446 (20.41%)	20,328 (16.12%)	20,298 (16.50%)	17,601 (16.91%)	136,563 (19.58%)
65 - 74 years	34,928 (20.47%)	34,936 (20.11%)	24,750 (19.63%)	24,523 (19.94%)	20,564 (19.76%)	139,701 (20.03%)
75 - 84 years	29,821 (17.48%)	34,277 (19.73%)	28,594 (22.68%)	28,710 (23.34%)	23,263 (22.35%)	144,665 (20.74%)
85+ years	17,301 (10.14%)	22,456 (12.93%)	20,455 (16.22%)	19,766 (16.07%)	15,132 (14.54%)	95,110 (13.64%)
Sex						
Female	83,414 (48.89%)	88,914 (51.19%)	65,940 (52.30%)	64,289 (52.26%)	54,816 (52.66%)	357,373 (51.24%)
Male	86,398 (50.64%)	83,971 (48.34%)	59,554 (47.24%)	58,116 (47.25%)	48,821 (46.90%)	336,860 (48.30%)
Other	3 (0.00%)	1 (0.00%)	4 (0.00%)	1 (0.00%)	1 (0.00%)	10 (0.00%)
Unknown	785 (0.46%)	823 (0.47%)	578 (0.46%)	603 (0.49%)	450 (0.43%)	3,239 (0.46%)
Race						
White	108,423 (63.55%)	115,772 (66.65%)	82,679 (65.58%)	79,269 (64.44%)	67,251 (64.61%)	453,394 (65.00%)
Black or African American	25,435 (14.91%)	23,286 (13.41%)	16,524 (13.11%)	17,356 (14.11%)	14,458 (13.89%)	97,059 (13.92%)
Asian	3,982 (2.33%)	3,936 (2.27%)	3,744 (2.97%)	3,453 (2.81%)	3,048 (2.93%)	18,163 (2.60%)
Native Hawaiian or Other Pacific Islander	876 (0.51%)	922 (0.53%)	655 (0.52%)	688 (0.56%)	662 (0.64%)	3,803 (0.55%)
American Indian or Alaska Native	1,037 (0.61%)	1,157 (0.67%)	832 (0.66%)	704 (0.57%)	661 (0.64%)	4,391 (0.63%)
Other Race	12,219 (7.16%)	10,349 (5.96%)	8,588 (6.81%)	8,463 (6.88%)	8,368 (8.04%)	47,987 (6.88%)
Unknown	18,628 (10.92%)	18,287 (10.53%)	13,054 (10.35%)	13,076 (10.63%)	9,640 (9.26%)	72,685 (10.42%)
Ethnicity						
Hispanic or Latino	21,206 (12.43%)	16,179 (9.31%)	12,594 (9.99%)	13,590 (11.05%)	13,806 (13.26%)	77,375 (11.09%)
Not Hispanic or Latino	129,635 (75.99%)	139,692 (80.42%)	101,333 (80.37%)	98,388 (79.98%)	82,878 (79.62%)	551,926 (79.13%)
Unknown	19,759 (11.58%)	17,838 (10.27%)	12,149 (9.64%)	11,031 (8.97%)	7,404 (7.11%)	68,181 (9.78%)
Virus						
COVID	157,766 (92.48%)	148,541 (85.51%)	71,732 (56.90%)	60,998 (49.59%)	30,970 (29.75%)	470,007 (67.39%)
HMPV	144 (0.08%)	2,803 (1.61%)	4,922 (3.90%)	4,221 (3.43%)	4,642 (4.46%)	16,732 (2.40%)
RSV	2,226 (1.30%)	4,398 (2.53%)	7,916 (6.28%)	9,738 (7.92%)	9,355 (8.99%)	33,633 (4.82%)
Influenza	1,262 (0.74%)	5,154 (2.97%)	20,173 (16.00%)	26,098 (21.22%)	35,341 (33.95%)	88,028 (12.62%)
Parainfluenza	1,595 (0.93%)	2,464 (1.42%)	4,655 (3.69%)	4,679 (3.80%)	4,672 (4.49%)	18,065 (2.59%)
Rhinovirus	7,607 (4.46%)	10,349 (5.96%)	16,678 (13.23%)	17,275 (14.04%)	19,108 (18.36%)	71,017 (10.18%)
Comorbidity						
Asthma	14,117 (8.27%)	17,129 (9.86%)	15,170 (12.03%)	16,218 (13.18%)	15,528 (14.92%)	78,162 (11.21%)
Chronic Lung Disease	10,065 (5.90%)	11,175 (6.43%)	9,181 (7.28%)	9,428 (7.66%)	9,197 (8.84%)	49,046 (7.03%)
Chronic Obstructive Pulmonary Disease	18,988 (11.13%)	25,820 (14.86%)	21,942 (17.40%)	23,109 (18.79%)	20,396 (19.59%)	110,255 (15.81%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations is shown in Figure 1. Figure 2 shows the same data stacked to represent the combined impact of the viruses.

Figure 1: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020



Figure 2: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020



Test positivity rate over time

We included 58,553,976 lab results with known results of which 5,440,397 were positive. The test positivity rate is shown in Figure 3.

Figure 3: Weekly test positivity rate since October 2020



COVID-19

Our COVID study population consists of 488,689 hospitalizations of 470,007 unique patients (Table 2).

Table 2: COVID patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	157,766 (100.00%)	148,541 (100.00%)	71,732 (100.00%)	60,998 (100.00%)	30,970 (100.00%)	470,007 (100.00%)
Age Group						
< 6 months	276 (0.17%)	643 (0.43%)	314 (0.44%)	359 (0.59%)	355 (1.15%)	1,947 (0.41%)
6 - <12 months	48 (0.03%)	177 (0.12%)	142 (0.20%)	176 (0.29%)	213 (0.69%)	756 (0.16%)
1 - <2 years	73 (0.05%)	175 (0.12%)	105 (0.15%)	231 (0.38%)	443 (1.43%)	1,027 (0.22%)
2 - 4 years	110 (0.07%)	254 (0.17%)	96 (0.13%)	249 (0.41%)	620 (2.00%)	1,329 (0.28%)
5 - 17 years	925 (0.59%)	1,252 (0.84%)	425 (0.59%)	563 (0.92%)	962 (3.11%)	4,127 (0.88%)
18 - 49 years	37,191 (23.57%)	31,990 (21.54%)	9,325 (13.00%)	6,666 (10.93%)	3,545 (11.45%)	88,717 (18.88%)
50 - 64 years	40,846 (25.89%)	31,646 (21.30%)	11,112 (15.49%)	8,970 (14.71%)	4,168 (13.46%)	96,742 (20.58%)
65 - 74 years	33,291 (21.10%)	31,175 (20.99%)	15,349 (21.40%)	13,080 (21.44%)	6,079 (19.63%)	98,974 (21.06%)
75 - 84 years	28,507 (18.07%)	30,917 (20.81%)	19,828 (27.64%)	17,721 (29.05%)	8,541 (27.58%)	105,514 (22.45%)
85+ years	16,499 (10.46%)	20,312 (13.67%)	15,036 (20.96%)	12,983 (21.28%)	6,044 (19.52%)	70,874 (15.08%)
Sex						
Female	76,842 (48.71%)	75,881 (51.08%)	37,008 (51.59%)	30,913 (50.68%)	15,804 (51.03%)	236,448 (50.31%)
Male	80,179 (50.82%)	71,921 (48.42%)	34,366 (47.91%)	29,723 (48.73%)	14,995 (48.42%)	231,184 (49.19%)
Other	3 (0.00%)	1 (0.00%)	2 (0.00%)	1 (0.00%)	0	7 (0.00%)
Unknown	742 (0.47%)	738 (0.50%)	356 (0.50%)	361 (0.59%)	171 (0.55%)	2,368 (0.50%)
Race						
White	100,915 (63.96%)	100,300 (67.52%)	50,034 (69.75%)	41,940 (68.76%)	20,224 (65.30%)	313,413 (66.68%)
Black or African American	23,183 (14.69%)	19,709 (13.27%)	8,145 (11.35%)	7,075 (11.60%)	3,953 (12.76%)	62,065 (13.21%)
Asian	3,597 (2.28%)	3,079 (2.07%)	1,804 (2.51%)	1,733 (2.84%)	1,148 (3.71%)	11,361 (2.42%)
Native Hawaiian or Other Pacific Islander	793 (0.50%)	699 (0.47%)	272 (0.38%)	257 (0.42%)	126 (0.41%)	2,147 (0.46%)
American Indian or Alaska Native	954 (0.60%)	944 (0.64%)	392 (0.55%)	340 (0.56%)	180 (0.58%)	2,810 (0.60%)
Other Race	10,796 (6.84%)	7,817 (5.26%)	3,533 (4.93%)	3,229 (5.29%)	2,315 (7.47%)	27,690 (5.89%)
Unknown	17,528 (11.11%)	15,993 (10.77%)	7,552 (10.53%)	6,424 (10.53%)	3,024 (9.76%)	50,521 (10.75%)
Ethnicity						
Hispanic or Latino	19,599 (12.42%)	12,880 (8.67%)	5,325 (7.42%)	5,205 (8.53%)	3,194 (10.31%)	46,203 (9.83%)
Not Hispanic or Latino	119,652 (75.84%)	120,146 (80.88%)	59,251 (82.60%)	50,209 (82.31%)	25,398 (82.01%)	374,656 (79.71%)
Unknown	18,515 (11.74%)	15,515 (10.44%)	7,156 (9.98%)	5,584 (9.15%)	2,378 (7.68%)	49,148 (10.46%)
Comorbidity						
Asthma	12,196 (7.73%)	13,376 (9.00%)	6,990 (9.74%)	6,596 (10.81%)	3,894 (12.57%)	43,052 (9.16%)
Chronic Lung Disease	9,125 (5.78%)	9,225 (6.21%)	5,087 (7.09%)	4,607 (7.55%)	2,396 (7.74%)	30,440 (6.48%)

Chronic Obstructive Pulmonary Disease	17,029 (10.79%)	21,654 (14.58%)	12,450 (17.36%)	11,624 (19.06%)	5,607 (18.10%)	68,364 (14.55%)

Hospitalization rate over time

The rate of COVID-associated hospitalization is shown in Figure 4. Figure 5 shows seasonal trends.

Figure 4: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions since October 2020



Figure 5: Rate of weekly COVID-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 29,529,278 COVID lab results with known results of which 3,267,006 were positive. The COVID test positivity rate is shown in Figure 6. Figure 7 shows yearly trends.

Figure 6: Weekly COVID test positivity rate since October 2020



Figure 7: Weekly COVID test positivity rate by season



Influenza

Our influenza study population consists of 102,382 hospitalizations of 88,028 unique patients (Table 3).

Table 3: Influenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	1,262 (100.00%)	5,154 (100.00%)	20,173 (100.00%)	26,098 (100.00%)	35,341 (100.00%)	88,028 (100.00%)
Age Group						
< 6 months	1 (0.08%)	23 (0.45%)	90 (0.45%)	96 (0.37%)	104 (0.29%)	314 (0.36%)
6 - <12 months	1 (0.08%)	18 (0.35%)	73 (0.36%)	72 (0.28%)	90 (0.25%)	254 (0.29%)
1 - <2 years	1 (0.08%)	27 (0.52%)	115 (0.57%)	106 (0.41%)	141 (0.40%)	390 (0.44%)
2 - 4 years	6 (0.48%)	59 (1.14%)	284 (1.41%)	259 (0.99%)	223 (0.63%)	831 (0.94%)
5 - 17 years	9 (0.71%)	163 (3.16%)	699 (3.47%)	773 (2.96%)	706 (2.00%)	2,350 (2.67%)
18 - 49 years	288 (22.82%)	1,155 (22.41%)	4,053 (20.09%)	5,395 (20.67%)	5,872 (16.62%)	16,763 (19.04%)
50 - 64 years	359 (28.45%)	1,018 (19.75%)	4,372 (21.67%)	5,853 (22.43%)	7,391 (20.91%)	18,993 (21.58%)
65 - 74 years	263 (20.84%)	1,073 (20.82%)	4,339 (21.51%)	5,586 (21.40%)	7,948 (22.49%)	19,209 (21.82%)
75 - 84 years	225 (17.83%)	994 (19.29%)	3,946 (19.56%)	5,176 (19.83%)	8,080 (22.86%)	18,421 (20.93%)
85+ years	109 (8.64%)	624 (12.11%)	2,202 (10.92%)	2,782 (10.66%)	4,786 (13.54%)	10,503 (11.93%)
Sex						
Female	687 (54.44%)	2,867 (55.63%)	11,179 (55.42%)	14,378 (55.09%)	19,253 (54.48%)	48,364 (54.94%)
Male	566 (44.85%)	2,255 (43.75%)	8,888 (44.06%)	11,601 (44.45%)	15,966 (45.18%)	39,276 (44.62%)

Other	0	0	2 (0.01%)	0	0	2 (0.00%)
Unknown	9 (0.71%)	32 (0.62%)	104 (0.52%)	119 (0.46%)	122 (0.35%)	386 (0.44%)
Race						
White	572 (45.32%)	3,306 (64.14%)	12,134 (60.15%)	15,214 (58.30%)	22,936 (64.90%)	54,162 (61.53%)
Black or African American	443 (35.10%)	847 (16.43%)	3,762 (18.65%)	5,299 (20.30%)	5,099 (14.43%)	15,450 (17.55%)
Asian	13 (1.03%)	107 (2.08%)	502 (2.49%)	637 (2.44%)	983 (2.78%)	2,242 (2.55%)
Native Hawaiian or Other Pacific Islander	3 (0.24%)	48 (0.93%)	121 (0.60%)	165 (0.63%)	193 (0.55%)	530 (0.60%)
American Indian or Alaska Native	3 (0.24%)	46 (0.89%)	152 (0.75%)	142 (0.54%)	248 (0.70%)	591 (0.67%)
Other Race	54 (4.28%)	298 (5.78%)	1,370 (6.79%)	1,813 (6.95%)	2,719 (7.69%)	6,254 (7.10%)
Unknown	174 (13.79%)	502 (9.74%)	2,132 (10.57%)	2,828 (10.84%)	3,163 (8.95%)	8,799 (10.00%)
Ethnicity						
Hispanic or Latino	38 (3.01%)	485 (9.41%)	2,052 (10.17%)	2,782 (10.66%)	4,401 (12.45%)	9,758 (11.09%)
Not Hispanic or Latino	1,039 (82.33%)	4,153 (80.58%)	16,115 (79.88%)	20,757 (79.53%)	28,369 (80.27%)	70,433 (80.01%)
Unknown	185 (14.66%)	516 (10.01%)	2,006 (9.94%)	2,559 (9.81%)	2,571 (7.27%)	7,837 (8.90%)
Comorbidity						
Asthma	105 (8.32%)	737 (14.30%)	2,935 (14.55%)	3,732 (14.30%)	5,189 (14.68%)	12,698 (14.42%)
Chronic Lung Disease	59 (4.68%)	420 (8.15%)	1,565 (7.76%)	1,975 (7.57%)	3,123 (8.84%)	7,142 (8.11%)
Chronic Obstructive Pulmonary Disease	209 (16.56%)	1,075 (20.86%)	4,017 (19.91%)	5,066 (19.41%)	7,379 (20.88%)	17,746 (20.16%)

Hospitalization rate over time

The rate of influenza-associated hospitalization is shown in Figure 8. Figure 9 shows seasonal trends.

Figure 8: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions since October 2020



Figure 9: Rate of weekly influenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 16,078,377 influenza lab results with known results of which 1,390,724 were positive. The influenza test positivity rate is shown in Figure 10. Figure 11 shows yearly trends.

Figure 10: Weekly influenza test positivity rate since October 2020



Figure 11: Weekly influenza test positivity rate by season



Human metapneumovirus (HMPV)

Our HMPV study population consists of 20,377 hospitalizations of 16,732 unique patients (Table 4).

Table 4: HMPV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	144 (100.00%)	2,803 (100.00%)	4,922 (100.00%)	4,221 (100.00%)	4,642 (100.00%)	16,732 (100.00%)
Age Group						
< 6 months	5 (3.47%)	86 (3.07%)	192 (3.90%)	113 (2.68%)	98 (2.11%)	494 (2.95%)
6 - <12 months	5 (3.47%)	126 (4.50%)	183 (3.72%)	141 (3.34%)	104 (2.24%)	559 (3.34%)
1 - <2 years	18 (12.50%)	176 (6.28%)	228 (4.63%)	138 (3.27%)	124 (2.67%)	684 (4.09%)
2 - 4 years	21 (14.58%)	283 (10.10%)	370 (7.52%)	193 (4.57%)	173 (3.73%)	1,040 (6.22%)
5 - 17 years	9 (6.25%)	145 (5.17%)	216 (4.39%)	148 (3.51%)	128 (2.76%)	646 (3.86%)
18 - 49 years	24 (16.67%)	324 (11.56%)	504 (10.24%)	515 (12.20%)	577 (12.43%)	1,944 (11.62%)
50 - 64 years	23 (15.97%)	474 (16.91%)	792 (16.09%)	703 (16.65%)	775 (16.70%)	2,767 (16.54%)
65 - 74 years	12 (8.33%)	467 (16.66%)	895 (18.18%)	786 (18.62%)	907 (19.54%)	3,067 (18.33%)
75 - 84 years	21 (14.58%)	446 (15.91%)	915 (18.59%)	895 (21.20%)	1,052 (22.66%)	3,329 (19.90%)
85+ years	6 (4.17%)	276 (9.85%)	627 (12.74%)	589 (13.95%)	704 (15.17%)	2,202 (13.16%)
Sex						
Female	70 (48.61%)	1,564 (55.80%)	2,843 (57.76%)	2,537 (60.10%)	2,697 (58.10%)	9,711 (58.04%)
Male	74 (51.39%)	1,229 (43.85%)	2,063 (41.91%)	1,671 (39.59%)	1,933 (41.64%)	6,970 (41.66%)
Unknown	0	10 (0.36%)	16 (0.33%)	13 (0.31%)	12 (0.26%)	51 (0.30%)
Race						
White	77 (53.47%)	1,893 (67.53%)	3,190 (64.81%)	2,732 (64.72%)	3,139 (67.62%)	11,031 (65.93%)
Black or African American	11 (7.64%)	290 (10.35%)	533 (10.83%)	492 (11.66%)	571 (12.30%)	1,897 (11.34%)
Asian	4 (2.78%)	75 (2.68%)	198 (4.02%)	127 (3.01%)	133 (2.87%)	537 (3.21%)
Native Hawaiian or Other Pacific Islander	1 (0.69%)	15 (0.54%)	18 (0.37%)	17 (0.40%)	20 (0.43%)	71 (0.42%)
American Indian or Alaska Native	2 (1.39%)	21 (0.75%)	39 (0.79%)	25 (0.59%)	22 (0.47%)	109 (0.65%)
Other Race	38 (26.39%)	272 (9.70%)	500 (10.16%)	388 (9.19%)	354 (7.63%)	1,552 (9.28%)
Unknown	11 (7.64%)	237 (8.46%)	444 (9.02%)	440 (10.42%)	403 (8.68%)	1,535 (9.17%)
Ethnicity						
Hispanic or Latino	36 (25.00%)	376 (13.41%)	714 (14.51%)	674 (15.97%)	715 (15.40%)	2,515 (15.03%)
Not Hispanic or Latino	97 (67.36%)	2,161 (77.10%)	3,839 (78.00%)	3,216 (76.19%)	3,638 (78.37%)	12,951 (77.40%)
Unknown	11 (7.64%)	266 (9.49%)	369 (7.50%)	331 (7.84%)	289 (6.23%)	1,266 (7.57%)
Comorbidity						
Asthma	14 (9.72%)	399 (14.23%)	762 (15.48%)	709 (16.80%)	780 (16.80%)	2,664 (15.92%)
Chronic Lung Disease	8 (5.56%)	262 (9.35%)	427 (8.68%)	380 (9.00%)	510 (10.99%)	1,587 (9.48%)
Chronic Obstructive Pulmonary Disease	14 (9.72%)	509 (18.16%)	885 (17.98%)	783 (18.55%)	968 (20.85%)	3,159 (18.88%)

Hospitalization rate over time

The rate of HMPV-associated hospitalization is shown in Figure 12. Figure 13 shows seasonal trends.

Figure 12: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions since October 2020



Figure 13: Rate of weekly HMPV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 2,116,702 HMPV lab results with known results of which 55,224 were positive. The HMPV test positivity rate is shown in Figure 14. Figure 15 shows yearly trends.

Figure 14: Weekly HMPV test positivity rate since October 2020

Figure 15: Weekly HMPV test positivity rate by season



Parainfluenza virus

Our parainfluenza study population consists of 22,682 hospitalizations of 18,065 unique patients (Table 5).

Table 5: Parainfluenza patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	1,595 (100.00%)	2,464 (100.00%)	4,655 (100.00%)	4,679 (100.00%)	4,672 (100.00%)	18,065 (100.00%)
Age Group						
< 6 months	100 (6.27%)	128 (5.19%)	223 (4.79%)	167 (3.57%)	141 (3.02%)	759 (4.20%)
6 - <12 months	80 (5.02%)	93 (3.77%)	167 (3.59%)	113 (2.42%)	85 (1.82%)	538 (2.98%)
1 - <2 years	121 (7.59%)	125 (5.07%)	204 (4.38%)	166 (3.55%)	138 (2.95%)	754 (4.17%)
2 - 4 years	125 (7.84%)	203 (8.24%)	299 (6.42%)	197 (4.21%)	160 (3.42%)	984 (5.45%)
5 - 17 years	85 (5.33%)	118 (4.79%)	254 (5.46%)	166 (3.55%)	147 (3.15%)	770 (4.26%)
18 - 49 years	229 (14.36%)	312 (12.66%)	538 (11.56%)	542 (11.58%)	593 (12.69%)	2,214 (12.26%)
50 - 64 years	274 (17.18%)	444 (18.02%)	775 (16.65%)	811 (17.33%)	797 (17.06%)	3,101 (17.17%)
65 - 74 years	252 (15.80%)	434 (17.61%)	797 (17.12%)	940 (20.09%)	961 (20.57%)	3,384 (18.73%)
75 - 84 years	196 (12.29%)	356 (14.45%)	838 (18.00%)	976 (20.86%)	1,008 (21.58%)	3,374 (18.68%)
85+ years	133 (8.34%)	251 (10.19%)	560 (12.03%)	601 (12.84%)	642 (13.74%)	2,187 (12.11%)
Sex						
Female	841 (52.73%)	1,354 (54.95%)	2,474 (53.15%)	2,536 (54.20%)	2,519 (53.92%)	9,724 (53.83%)
Male	746 (46.77%)	1,106 (44.89%)	2,161 (46.42%)	2,128 (45.48%)	2,135 (45.70%)	8,276 (45.81%)
Unknown	8 (0.50%)	4 (0.16%)	20 (0.43%)	15 (0.32%)	18 (0.39%)	65 (0.36%)
Race						
White	1,023 (64.14%)	1,545 (62.70%)	2,902 (62.34%)	2,980 (63.69%)	3,115 (66.67%)	11,565 (64.02%)
Black or African American	205 (12.85%)	302 (12.26%)	562 (12.07%)	588 (12.57%)	571 (12.22%)	2,228 (12.33%)
Asian	43 (2.70%)	99 (4.02%)	195 (4.19%)	137 (2.93%)	119 (2.55%)	593 (3.28%)
Native Hawaiian or Other Pacific Islander	6 (0.38%)	13 (0.53%)	21 (0.45%)	38 (0.81%)	21 (0.45%)	99 (0.55%)
American Indian or Alaska Native	14 (0.88%)	20 (0.81%)	40 (0.86%)	31 (0.66%)	29 (0.62%)	134 (0.74%)
Other Race	167 (10.47%)	248 (10.06%)	499 (10.72%)	388 (8.29%)	379 (8.11%)	1,681 (9.31%)
Unknown	137 (8.59%)	237 (9.62%)	436 (9.37%)	517 (11.05%)	438 (9.38%)	1,765 (9.77%)
Ethnicity						
Hispanic or Latino	186 (11.66%)	308 (12.50%)	660 (14.18%)	684 (14.62%)	666 (14.26%)	2,504 (13.86%)
Not Hispanic or Latino	1,240 (77.74%)	1,920 (77.92%)	3,550 (76.26%)	3,598 (76.90%)	3,708 (79.37%)	14,016 (77.59%)
Unknown	169 (10.60%)	236 (9.58%)	445 (9.56%)	397 (8.48%)	298 (6.38%)	1,545 (8.55%)
Comorbidity						
Asthma	220 (13.79%)	373 (15.14%)	700 (15.04%)	739 (15.79%)	759 (16.25%)	2,791 (15.45%)
Chronic Lung Disease	143 (8.97%)	251 (10.19%)	422 (9.07%)	471 (10.07%)	535 (11.45%)	1,822 (10.09%)
Chronic Obstructive Pulmonary Disease	301 (18.87%)	506 (20.54%)	936 (20.11%)	1,111 (23.74%)	1,115 (23.87%)	3,969 (21.97%)

Hospitalization rate over time

The rate of parainfluenza-associated hospitalization is shown in Figure 16. Figure 17 shows seasonal trends.

Figure 16: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions since October 2020

Figure 17: Rate of weekly parainfluenza-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 2,221,343 parainfluenza lab results with known results of which 85,768 were positive. The parainfluenza test positivity rate is shown in Figure 18. Figure 19 shows yearly trends.

Figure 18: Weekly parainfluenza test positivity rate since October 2020

Figure 19: Weekly parainfluenza test positivity rate by season



Respiratory syncytial virus (RSV)

Our RSV study population consists of 43,458 hospitalizations of 33,633 unique patients (Table 6).

Table 6: RSV patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	2,226 (100.00%)	4,398 (100.00%)	7,916 (100.00%)	9,738 (100.00%)	9,355 (100.00%)	33,633 (100.00%)
Age Group						
< 6 months	546 (24.53%)	768 (17.46%)	1,463 (18.48%)	1,132 (11.62%)	738 (7.89%)	4,647 (13.82%)
6 - <12 months	185 (8.31%)	310 (7.05%)	532 (6.72%)	498 (5.11%)	422 (4.51%)	1,947 (5.79%)
1 - <2 years	208 (9.34%)	351 (7.98%)	619 (7.82%)	512 (5.26%)	466 (4.98%)	2,156 (6.41%)
2 - 4 years	179 (8.04%)	369 (8.39%)	661 (8.35%)	447 (4.59%)	503 (5.38%)	2,159 (6.42%)
5 - 17 years	46 (2.07%)	128 (2.91%)	248 (3.13%)	212 (2.18%)	217 (2.32%)	851 (2.53%)
18 - 49 years	225 (10.11%)	403 (9.16%)	664 (8.39%)	855 (8.78%)	942 (10.07%)	3,089 (9.18%)
50 - 64 years	272 (12.22%)	538 (12.23%)	870 (10.99%)	1,396 (14.34%)	1,409 (15.06%)	4,485 (13.34%)
65 - 74 years	243 (10.92%)	552 (12.55%)	1,023 (12.92%)	1,587 (16.30%)	1,617 (17.28%)	5,022 (14.93%)
75 - 84 years	197 (8.85%)	597 (13.57%)	1,080 (13.64%)	1,735 (17.82%)	1,800 (19.24%)	5,409 (16.08%)
85+ years	125 (5.62%)	382 (8.69%)	756 (9.55%)	1,364 (14.01%)	1,241 (13.27%)	3,868 (11.50%)
Sex						
Female	1,206 (54.18%)	2,270 (51.61%)	4,201 (53.07%)	5,350 (54.94%)	5,146 (55.01%)	18,173 (54.03%)
Male	1,016 (45.64%)	2,115 (48.09%)	3,697 (46.70%)	4,356 (44.73%)	4,176 (44.64%)	15,360 (45.67%)
Unknown	4 (0.18%)	13 (0.30%)	18 (0.23%)	32 (0.33%)	33 (0.35%)	100 (0.30%)
Race						
White	1,376 (61.81%)	2,807 (63.82%)	4,860 (61.39%)	6,313 (64.83%)	5,997 (64.10%)	21,353 (63.49%)
Black or African American	361 (16.22%)	527 (11.98%)	906 (11.45%)	1,176 (12.08%)	1,228 (13.13%)	4,198 (12.48%)
Asian	55 (2.47%)	166 (3.77%)	363 (4.59%)	331 (3.40%)	266 (2.84%)	1,181 (3.51%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Native Hawaiian or Other Pacific Islander	16 (0.72%)	78 (1.77%)	153 (1.93%)	110 (1.13%)	174 (1.86%)	531 (1.58%)
American Indian or Alaska Native	15 (0.67%)	40 (0.91%)	67 (0.85%)	63 (0.65%)	53 (0.57%)	238 (0.71%)
Other Race	234 (10.51%)	376 (8.55%)	761 (9.61%)	708 (7.27%)	767 (8.20%)	2,846 (8.46%)
Unknown	169 (7.59%)	404 (9.19%)	806 (10.18%)	1,037 (10.65%)	870 (9.30%)	3,286 (9.77%)
Ethnicity						
Hispanic or Latino	329 (14.78%)	574 (13.05%)	1,207 (15.25%)	1,208 (12.41%)	1,412 (15.09%)	4,730 (14.06%)
Not Hispanic or Latino	1,714 (77.00%)	3,435 (78.10%)	6,044 (76.35%)	7,709 (79.16%)	7,284 (77.86%)	26,186 (77.86%)
Unknown	183 (8.22%)	389 (8.84%)	665 (8.40%)	821 (8.43%)	659 (7.04%)	2,717 (8.08%)
Comorbidity						
Asthma	241 (10.83%)	536 (12.19%)	975 (12.32%)	1,356 (13.92%)	1,448 (15.48%)	4,556 (13.55%)
Chronic Lung Disease	130 (5.84%)	292 (6.64%)	501 (6.33%)	720 (7.39%)	863 (9.23%)	2,506 (7.45%)
Chronic Obstructive Pulmonary Disease	284 (12.76%)	670 (15.23%)	1,209 (15.27%)	1,870 (19.20%)	1,936 (20.69%)	5,969 (17.75%)

Hospitalization rate over time

The rate of RSV-associated hospitalization is shown in Figure 20. Figure 21 shows seasonal trends.

Figure 20: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions since October 2020



Figure 21: Rate of weekly RSV-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 6,476,898 RSV lab results with known results of which 296,540 were positive. The RSV test positivity rate is shown in Figure 22. Figure 23 shows yearly trends.

Figure 22: Weekly RSV test positivity rate since October 2020



Figure 23: Weekly RSV test positivity rate by season



Rhinovirus

Our rhinovirus study population consists of 90,318 hospitalizations of 71,017 unique patients (Table 7).

Table 7: Rhinovirus patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	7,607 (100.00%)	10,349 (100.00%)	16,678 (100.00%)	17,275 (100.00%)	19,108 (100.00%)	71,017 (100.00%)
Age Group						
< 6 months	513 (6.74%)	760 (7.34%)	999 (5.99%)	931 (5.39%)	825 (4.32%)	4,028 (5.67%)
6 - <12 months	323 (4.25%)	435 (4.20%)	539 (3.23%)	516 (2.99%)	432 (2.26%)	2,245 (3.16%)
1 - <2 years	613 (8.06%)	834 (8.06%)	958 (5.74%)	908 (5.26%)	823 (4.31%)	4,136 (5.82%)
2 - 4 years	723 (9.50%)	1,346 (13.01%)	1,510 (9.05%)	1,272 (7.36%)	1,128 (5.90%)	5,979 (8.42%)
5 - 17 years	845 (11.11%)	1,313 (12.69%)	1,933 (11.59%)	1,866 (10.80%)	1,653 (8.65%)	7,610 (10.72%)
18 - 49 years	1,503 (19.76%)	1,522 (14.71%)	2,724 (16.33%)	3,019 (17.48%)	3,637 (19.03%)	12,405 (17.47%)
50 - 64 years	1,116 (14.67%)	1,326 (12.81%)	2,407 (14.43%)	2,565 (14.85%)	3,061 (16.02%)	10,475 (14.75%)
65 - 74 years	867 (11.40%)	1,235 (11.93%)	2,347 (14.07%)	2,544 (14.73%)	3,052 (15.97%)	10,045 (14.14%)
75 - 84 years	675 (8.87%)	967 (9.34%)	1,987 (11.91%)	2,207 (12.78%)	2,782 (14.56%)	8,618 (12.14%)
85+ years	429 (5.64%)	611 (5.90%)	1,274 (7.64%)	1,447 (8.38%)	1,715 (8.98%)	5,476 (7.71%)
Sex						
Female	3,768 (49.53%)	4,978 (48.10%)	8,235 (49.38%)	8,575 (49.64%)	9,397 (49.18%)	34,953 (49.22%)
Male	3,817 (50.18%)	5,345 (51.65%)	8,379 (50.24%)	8,637 (50.00%)	9,616 (50.32%)	35,794 (50.40%)
Other	0	0	0	0	1 (0.01%)	1 (0.00%)
Unknown	22 (0.29%)	26 (0.25%)	64 (0.38%)	63 (0.36%)	94 (0.49%)	269 (0.38%)
Race						
White	4,460 (58.63%)	5,921 (57.21%)	9,559 (57.32%)	10,090 (58.41%)	11,840 (61.96%)	41,870 (58.96%)
Black or African American	1,232 (16.20%)	1,611 (15.57%)	2,616 (15.69%)	2,726 (15.78%)	3,036 (15.89%)	11,221 (15.80%)
Asian	270 (3.55%)	410 (3.96%)	682 (4.09%)	488 (2.82%)	399 (2.09%)	2,249 (3.17%)
Native Hawaiian or Other Pacific Islander	57 (0.75%)	69 (0.67%)	70 (0.42%)	101 (0.58%)	128 (0.67%)	425 (0.60%)
American Indian or Alaska Native	49 (0.64%)	86 (0.83%)	142 (0.85%)	103 (0.60%)	129 (0.68%)	509 (0.72%)
Other Race	930 (12.23%)	1,338 (12.93%)	1,925 (11.54%)	1,937 (11.21%)	1,834 (9.60%)	7,964 (11.21%)
Unknown	609 (8.01%)	914 (8.83%)	1,684 (10.10%)	1,830 (10.59%)	1,742 (9.12%)	6,779 (9.55%)
Ethnicity						
Hispanic or Latino	1,018 (13.38%)	1,556 (15.04%)	2,636 (15.81%)	3,037 (17.58%)	3,418 (17.89%)	11,665 (16.43%)
Not Hispanic or Latino	5,893 (77.47%)	7,877 (76.11%)	12,534 (75.15%)	12,899 (74.67%)	14,481 (75.79%)	53,684 (75.59%)
Unknown	696 (9.15%)	916 (8.85%)	1,508 (9.04%)	1,339 (7.75%)	1,209 (6.33%)	5,668 (7.98%)
Comorbidity						
Asthma	1,341 (17.63%)	1,708 (16.50%)	2,808 (16.84%)	3,086 (17.86%)	3,458 (18.10%)	12,401 (17.46%)
Chronic Lung Disease	600 (7.89%)	725 (7.01%)	1,179 (7.07%)	1,275 (7.38%)	1,770 (9.26%)	5,549 (7.81%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Chronic Obstructive Pulmonary Disease	1,151 (15.13%)	1,406 (13.59%)	2,445 (14.66%)	2,655 (15.37%)	3,391 (17.75%)	11,048 (15.56%)

Hospitalization rate over time

The rate of rhinovirus-associated hospitalization is shown in Figure 24. Figure 25 shows seasonal trends.

Figure 24: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions since October 2020

Figure 25: Rate of weekly rhinovirus-associated hospitalizations compared to all hospital admissions by season



Test positivity rate over time

We included 2,131,378 rhinovirus lab results with known results of which 345,135 were positive. The rhinovirus test positivity rate is shown in Figure 26. Figure 27 shows yearly trends.

Figure 26: Weekly rhinovirus test positivity rate since October 2020

Figure 27: Weekly rhinovirus test positivity rate by season



Infants and children (age 0-4)

Our infants and children study population consists of 53,023 hospitalizations of 39,957 unique patients (Table 8).

Table 8: Infants and children patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	4,281 (100.00%)	7,769 (100.00%)	10,366 (100.00%)	8,992 (100.00%)	8,549 (100.00%)	39,957 (100.00%)
Age Group						
< 6 months	1,441 (33.66%)	2,408 (30.99%)	3,281 (31.65%)	2,798 (31.12%)	2,261 (26.45%)	12,189 (30.51%)
6 - <12 months	642 (15.00%)	1,159 (14.92%)	1,636 (15.78%)	1,516 (16.86%)	1,346 (15.74%)	6,299 (15.76%)
1 - <2 years	1,034 (24.15%)	1,688 (21.73%)	2,229 (21.50%)	2,061 (22.92%)	2,135 (24.97%)	9,147 (22.89%)
2 - 4 years	1,164 (27.19%)	2,514 (32.36%)	3,220 (31.06%)	2,617 (29.10%)	2,807 (32.83%)	12,322 (30.84%)
Sex						
Female	1,822 (42.56%)	3,225 (41.51%)	4,443 (42.86%)	3,905 (43.43%)	3,710 (43.40%)	17,105 (42.81%)
Male	2,459 (57.44%)	4,542 (58.46%)	5,922 (57.13%)	5,084 (56.54%)	4,837 (56.58%)	22,844 (57.17%)
Unknown	0	2 (0.03%)	1 (0.01%)	3 (0.03%)	2 (0.02%)	8 (0.02%)
Race						

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
White	2,174 (50.78%)	3,841 (49.44%)	4,814 (46.44%)	4,220 (46.93%)	3,985 (46.61%)	19,034 (47.64%)
Black or African American	730 (17.05%)	1,189 (15.30%)	1,603 (15.46%)	1,429 (15.89%)	1,369 (16.01%)	6,320 (15.82%)
Asian	198 (4.63%)	452 (5.82%)	738 (7.12%)	491 (5.46%)	409 (4.78%)	2,288 (5.73%)
Native Hawaiian or Other Pacific Islander	81 (1.89%)	179 (2.30%)	234 (2.26%)	231 (2.57%)	250 (2.92%)	975 (2.44%)
American Indian or Alaska Native	36 (0.84%)	93 (1.20%)	131 (1.26%)	65 (0.72%)	70 (0.82%)	395 (0.99%)
Other Race	803 (18.76%)	1,364 (17.56%)	1,840 (17.75%)	1,533 (17.05%)	1,599 (18.70%)	7,139 (17.87%)
Unknown	259 (6.05%)	651 (8.38%)	1,006 (9.70%)	1,023 (11.38%)	867 (10.14%)	3,806 (9.53%)
Ethnicity						
Hispanic or Latino	913 (21.33%)	1,662 (21.39%)	2,556 (24.66%)	2,335 (25.97%)	2,447 (28.62%)	9,913 (24.81%)
Not Hispanic or Latino	3,060 (71.48%)	5,490 (70.67%)	7,064 (68.15%)	6,091 (67.74%)	5,498 (64.31%)	27,203 (68.08%)
Unknown	308 (7.19%)	617 (7.94%)	746 (7.20%)	566 (6.29%)	604 (7.07%)	2,841 (7.11%)
Virus						
COVID	507 (11.84%)	1,249 (16.08%)	657 (6.34%)	1,015 (11.29%)	1,631 (19.08%)	5,059 (12.66%)
HMPV	49 (1.14%)	671 (8.64%)	973 (9.39%)	585 (6.51%)	499 (5.84%)	2,777 (6.95%)
RSV	1,118 (26.12%)	1,798 (23.14%)	3,275 (31.59%)	2,589 (28.79%)	2,129 (24.90%)	10,909 (27.30%)
influenza	9 (0.21%)	127 (1.63%)	562 (5.42%)	533 (5.93%)	558 (6.53%)	1,789 (4.48%)
parainfluenza	426 (9.95%)	549 (7.07%)	893 (8.61%)	643 (7.15%)	524 (6.13%)	3,035 (7.60%)
rhinovirus	2,172 (50.74%)	3,375 (43.44%)	4,006 (38.65%)	3,627 (40.34%)	3,208 (37.52%)	16,388 (41.01%)
Comorbidity						
Asthma	324 (7.57%)	492 (6.33%)	712 (6.87%)	718 (7.98%)	788 (9.22%)	3,034 (7.59%)
Chronic Lung Disease	26 (0.61%)	51 (0.66%)	79 (0.76%)	66 (0.73%)	56 (0.66%)	278 (0.70%)
Chronic Obstructive Pulmonary Disease	6 (0.14%)	15 (0.19%)	16 (0.15%)	18 (0.20%)	13 (0.15%)	68 (0.17%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for infants and children under five is shown in Figure 28. Figure 29 shows the same data stacked to represent the combined impact of the viruses.

Figure 28: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five



Figure 29: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for infants and children under five



Test positivity rate over time

We included 6,408,307 lab results with known results of infants and children under age five. Of those tests, 734,429 lab results were positive. The test positivity rate for infants and children under age five is shown in Figure 30.

Figure 30: Weekly test positivity rate since October 2020 for infants and children under five



Older adults (age 65 and over)

Our older adults study population consists of 412,906 hospitalizations of 379,476 unique patients (Table 9).

Table 9: Older adults patient characteristics by season.

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
N	82,050 (100.00%)	91,669 (100.00%)	73,799 (100.00%)	72,999 (100.00%)	58,959 (100.00%)	379,476 (100.00%)
Age Group						
65 - 74 years	34,928 (42.57%)	34,936 (38.11%)	24,750 (33.54%)	24,523 (33.59%)	20,564 (34.88%)	139,701 (36.81%)
75 - 84 years	29,821 (36.34%)	34,277 (37.39%)	28,594 (38.75%)	28,710 (39.33%)	23,263 (39.46%)	144,665 (38.12%)
85+ years	17,301 (21.09%)	22,456 (24.50%)	20,455 (27.72%)	19,766 (27.08%)	15,132 (25.67%)	95,110 (25.06%)
Sex						
Female	40,216 (49.01%)	45,807 (49.97%)	38,822 (52.61%)	38,266 (52.42%)	31,580 (53.56%)	194,691 (51.31%)
Male	41,530 (50.62%)	45,500 (49.64%)	34,685 (47.00%)	34,392 (47.11%)	27,116 (45.99%)	183,223 (48.28%)
Unknown	304 (0.37%)	362 (0.39%)	292 (0.40%)	341 (0.47%)	263 (0.45%)	1,562 (0.41%)
Race						
White	59,243 (72.20%)	68,782 (75.03%)	54,996 (74.52%)	53,121 (72.77%)	43,324 (73.48%)	279,466 (73.65%)
Black or African American	9,164 (11.17%)	8,933 (9.74%)	6,674 (9.04%)	7,253 (9.94%)	5,614 (9.52%)	37,638 (9.92%)
Asian	1,401 (1.71%)	1,528 (1.67%)	1,649 (2.23%)	1,774 (2.43%)	1,605 (2.72%)	7,957 (2.10%)
Native Hawaiian or Other Pacific Islander	134 (0.16%)	173 (0.19%)	133 (0.18%)	143 (0.20%)	136 (0.23%)	719 (0.19%)
American Indian or Alaska Native	217 (0.26%)	295 (0.32%)	281 (0.38%)	267 (0.37%)	242 (0.41%)	1,302 (0.34%)
Other Race	2,937 (3.58%)	2,687 (2.93%)	2,677 (3.63%)	3,067 (4.20%)	2,955 (5.01%)	14,323 (3.77%)
Unknown	8,954 (10.91%)	9,271 (10.11%)	7,389 (10.01%)	7,374 (10.10%)	5,083 (8.62%)	38,071 (10.03%)
Ethnicity						
Hispanic or Latino	4,278 (5.21%)	3,697 (4.03%)	3,682 (4.99%)	4,485 (6.14%)	4,373 (7.42%)	20,515 (5.41%)
Not Hispanic or Latino	67,240 (81.95%)	78,059 (85.15%)	62,629 (84.86%)	61,554 (84.32%)	50,233 (85.20%)	319,715 (84.25%)
Unknown	10,532 (12.84%)	9,913 (10.81%)	7,488 (10.15%)	6,960 (9.53%)	4,353 (7.38%)	39,246 (10.34%)
Virus						
COVID	78,297 (95.43%)	82,404 (89.89%)	50,213 (68.04%)	43,784 (59.98%)	20,664 (35.05%)	275,362 (72.56%)
HMPV	39 (0.05%)	1,189 (1.30%)	2,437 (3.30%)	2,270 (3.11%)	2,663 (4.52%)	8,598 (2.27%)
RSV	565 (0.69%)	1,531 (1.67%)	2,859 (3.87%)	4,686 (6.42%)	4,658 (7.90%)	14,299 (3.77%)
influenza	597 (0.73%)	2,691 (2.94%)	10,487 (14.21%)	13,544 (18.55%)	20,814 (35.30%)	48,133 (12.68%)
parainfluenza	581 (0.71%)	1,041 (1.14%)	2,195 (2.97%)	2,517 (3.45%)	2,611 (4.43%)	8,945 (2.36%)
rhinovirus	1,971 (2.40%)	2,813 (3.07%)	5,608 (7.60%)	6,198 (8.49%)	7,549 (12.80%)	24,139 (6.36%)
Comorbidity						
Asthma	6,244 (7.61%)	8,046 (8.78%)	7,565 (10.25%)	8,137 (11.15%)	7,500 (12.72%)	37,492 (9.88%)
Chronic Lung Disease	5,837 (7.11%)	6,942 (7.57%)	6,293 (8.53%)	6,438 (8.82%)	6,265 (10.63%)	31,775 (8.37%)

	2020/2021	2021/2022	2022/2023	2023/2024	2024/2025	Overall
Chronic Obstructive Pulmonary Disease	14,126 (17.22%)	19,250 (21.00%)	16,777 (22.73%)	17,825 (24.42%)	15,498 (26.29%)	83,476 (22.00%)

Hospitalization rate over time

The rate of respiratory virus-associated hospitalizations compared to all hospitalizations for adults 65 and over is shown in `Figure 31. Figure 32 shows the same data stacked to represent the combined impact of the viruses.

Figure 31: Rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older



Figure 32: Cumulative rate of weekly respiratory virus-associated hospitalizations compared to all hospital admissions since October 2020 for adults 65 years or older



Test positivity rate over time

We included 17,126,768 lab results with known results of adults aged 65 and over. Of those tests, 1,185,993 lab results were positive. The test positivity rate for adults aged 65 and over is shown in Figure 33.

Figure 33: Weekly test positivity rate since October 2020 for adults 65 years or older



Discussion and conclusion

In the last week of September 2025, respiratory virus-associated hospitalizations accounted for 1.9% of all hospitalizations, a decrease from 2.6% at the beginning of the month (-27.1%). COVID-associated hospitalizations saw the largest decrease (-45.1%). Influenza-, HMPV-, parainfluenza-, RSV-, and rhinovirus-associated hospitalizations all remained stable across the month. RSV and parainfluenza test positivity increased notably (+95.1% and +64.7%, respectively), while COVID test positivity fell sharply (–57.7%). Influenza test positivity increased slightly (+17.8%), HMPV remained steady, and rhinovirus continued to show the highest positivity levels (20.9%). These data suggest that respiratory virus–associated hospitalizations remained low overall; at the end of September rhinovirus accounted for the largest proportion of virus-associated hospitalizations and had the highest rate of test positivity.

In the population aged 0–4 years, respiratory virus–associated hospitalizations remained relatively stable throughout September 2025 and are now at a rate of 2.3% of all hospitalizations in this age group. RSV-associated hospitalizations rose but continued to represent a small proportion of all hospitalizations within this age group (0.3%). COVID-associated hospitalizations increased during the first half of the month, but declined slightly overall to 0.6% (-13.0%). Rhinovirus-associated hospitalizations rose during the first half of the month, declined in the second half, but ended the month 14.6% higher than at the start. Rhinovirus remained the most common viral cause of hospitalization (1.7%). HMPV and parainfluenza-associated hospitalizations were largely unchanged. In this pediatric population RSV test positivity more than doubled (+114.9%), and parainfluenza increased moderately (+51.4%). COVID test positivity declined sharply (-60.0%), while influenza and HMPV rose slightly (+23.2% and +25.5%, respectively). Rhinovirus remained the virus with the highest test positivity rate (49.4%) despite a slight decrease (-6.5%). These data suggest that respiratory virus–associated hospitalizations are at moderate levels among young children, with rhinovirus accounting for the largest proportion in both hospitalizations and test

positivity, and RSV and parainfluenza showing a moderate increase in test positivity late in the month.

Among adults aged 65 years and older, respiratory virus–associated hospitalizations accounted for 2.0% of all hospitalizations in the last week of September 2025, a decrease from 3.2% at the beginning of the month (-35.9%). COVID-associated hospitalizations represented 1.1% of all hospitalizations in this age group and saw a steady decline across the month, while rhinovirus-associated hospitalizations were stable and accounted for 0.8% of all hospitalizations. RSV-, HMPV-, influenza-, and parainfluenza-associated hospitalizations remained low and stable throughout the month. COVID test positivity declined substantially (–48.2%). Influenza-, HMPV-, and RSV positivity remained stable, while rhinovirus continued to show the highest positivity levels (9.3%) with a modest increase (+13.1%). These data suggest that respiratory virus–associated hospitalizations remained low among older adults, with COVID and rhinovirus accounting for the largest proportions in both hospitalizations and test positivity.

Several limitations of our analysis should be noted. All data are preliminary and may change as additional data are obtained. These findings are consistent with data accessed October 21, 2025. These are raw counts and post-stratification methods have not been conducted. This analysis does not include patients hospitalized with a respiratory virus who were not tested or were tested later in their medical care (when laboratory tests results would have returned a negative result). In addition, cohorts with small counts may be suppressed during the de-identification process leading to the appearance of zero patients for a given time period. Moreover, the unknowns in this report either indicate the value was not included in the individual's electronic health record or that it was excluded from the data to protect an individual's identity as a part of Truveta's commitment to privacy (Truveta, 2024).

We will continue to monitor respiratory virus-associated hospitalization overall and for the at-risk populations.

References

Boyce, T. G., Mellen, B. G., Mitchel, E. F., Wright, P. F., & Griffin, M. R. (2000). Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. The Journal of Pediatrics, 137(6), 865-870. https://doi.org/10.1067/mpd.2000.110531

Centers for Disease Control and Prevention. (2023a, April 10). Past seasons estimated influenza disease burden. Table Print. https://www.cdc.gov/flu/about/burden/past-seasons.html

Centers for Disease Control and Prevention. (2023b, April 4). The National Respiratory and Enteric Virus Surveillance System (NREVSS). Dashboard Print. https://www.cdc.gov/surveillance/nrevss/index.html

Centers for Disease Control and Prevention. (2023c, April 10). Influenza Hospitalization Surveillance Network (FluSurv-NET). Interactive Dashboard Print. https://www.cdc.gov/flu/weekly/influenza-hospitalization-surveillance.htm

Centers for Disease Control and Prevention. (2023d, April 10). RSV-NET Interactive Dashboard Print. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html

Committee on Infectious Diseases and Bronchiolitis Guidelines Committee, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., Sawyer, M. H., Schutze, G. E., Willoughby, R. E., Zaoutis, T. E., Ralston, S. L., Lieberthal, A. S., Meissner, H. C., Alverson, B. K., Baley, J. E., ... Hernández-Cancio, S. (2014). Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics, 134(2), e620-e638. https://doi.org/10.1542/peds.2014-1666

Christopher A Czaja, Lisa Miller, Nisha Alden, Heidi L Wald, Charisse Nitura Cummings, Melissa A Rolfes, Evan J Anderson, Nancy M Bennett, Laurie M Billing, Shua J Chai, Seth Eckel, Robert Mansmann, Melissa McMahon, Maya L Monroe, Alison Muse, Ilene Risk, William Schaffner, Ann R Thomas, Kimberly Yousey-Hindes, Shikha Garg, Rachel K Herlihy, Age-Related Differences in Hospitalization Rates, Clinical Presentation, and Outcomes Among Older Adults Hospitalized With Influenza—U.S. Influenza Hospitalization Surveillance Network (FluSurv-NET), Open Forum Infectious Diseases, Volume 6, Issue 7, July 2019, ofz225, https://doi.org/10.1093/ofid/ofz225

Lee, N., Lui, G. C. Y., Wong, K. T., Li, T. C. M., Tse, E. C. M., Chan, J. Y. C., Yu, J., Wong, S. S. M., Choi, K. W., Wong, R. Y. K., Ngai, K. L. K., Hui, D. S. C., & Chan, P. K. S. (2013). High Morbidity and Mortality in Adults Hospitalized for Respiratory Syncytial Virus Infections. Clinical Infectious Diseases, 57(8), 1069–1077. https://doi.org/10.1093/cid/cit471

Pastula, S. T., Hackett, J., Coalson, J., Jiang, X., Villafana, T., Ambrose, C., & Fryzek, J. (2017). Hospitalizations for Respiratory Syncytial Virus Among Adults in the United States, 1997–2012. Open Forum Infectious Diseases, 4(1), ofw270. https://doi.org/10.1093/ofid/ofw270

Shi, T., McAllister, D. A., O'Brien, K. L., Simoes, E. A. F., Madhi, S. A., Gessner, B. D., Polack, F. P., Balsells, E., Acacio, S., Aguayo, C., Alassani, I., Ali, A., Antonio, M., Awasthi, S., Awori, J. O., Azziz-Baumgartner, E., Baggett, H. C., Baillie, V. L., Balmaseda, A., ... Nair, H.

(2017). Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: A systematic review and modelling study. The Lancet, 390(10098), 946–958. https://doi.org/10.1016/S0140-6736(17)30938-8

Smits PD, Gratzl S, Simonov M, Nachimuthu SK, Goodwin Cartwright BM, Wang MD, Baker C, Rodriguez P, Bogiages M, Althouse BM, Stucky NL. Risk of COVID-19 breakthrough infection and hospitalization in individuals with comorbidities. Vaccine. 2023 Apr 6;41(15):2447-2455. https://doi.org/10.1016/j.vaccine.2023.02.038. Epub 2023 Feb 16. PMID: 36803895; PMCID: PMC9933320.

Tokars JI, Olsen SJ, Reed C. Seasonal Incidence of Symptomatic Influenza in the United States. Clin Infect Dis. 2018 May 2;66(10):1511-1518. https://doi.org/10.1093/cid/cix1060. PMID: 29206909; PMCID: PMC5934309.

Truveta. (2024). Truveta's Approach to Patient Privacy. https://resources.truveta.com/patient-privacy